公开(公告)号：US12138302B2

公开(公告)日：2024-11-12

申请号：US17509110

申请日：2021-10-25

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Robert George Konrad Donald ,  Jacqueline Marie Lypowy ,  Rosalind Pan

IPC: A61K39/108 ,  A61K39/00 ,  A61P31/04 ,  A61P37/04

Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.

公开(公告)号：US20230321212A1

公开(公告)日：2023-10-12

申请号：US18042561

申请日：2021-08-23

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Robert George Konrad Donald ,  Julio Cesar Hawkins ,  Srinivas Kodali ,  Raphael Simon

IPC: A61K39/09 ,  A61P37/04

CPC classification number: A61K39/092 ,  A61P37/04 ,  A61K2039/6031

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

公开(公告)号：US20250114442A1

公开(公告)日：2025-04-10

申请号：US18828443

申请日：2024-09-09

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Robert George Konrad Donald ,  Jacqueline Marie Lypowy ,  Rosalind Pan

IPC: A61K39/108 ,  A61K39/00 ,  A61P31/04 ,  A61P37/04

Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.

公开(公告)号：US20220202923A1

公开(公告)日：2022-06-30

申请号：US17554424

申请日：2021-12-17

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Laurent Oliver Chorro ,  Robert George Konrad Donald ,  Matthew Curtis Griffor ,  Natalie Clare Silmon de Monerri

IPC: A61K39/108 ,  C07K14/245 ,  C07K16/12

Abstract: This disclosure relates to the design of E. coli mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.

公开(公告)号：US20250000960A1

公开(公告)日：2025-01-02

申请号：US18739401

申请日：2024-06-11

Applicant: Pfizer Inc.

Inventor： Eric Matthew Bennett ,  Robert George Konrad Donald ,  Laura Lin Lohse ,  Natalie Clare Silmon de Monerri

IPC: A61K39/108 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K39/00 ,  A61P31/04 ,  C07K14/245 ,  C12N15/11

Abstract: The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.

公开(公告)号：US20240263132A1

公开(公告)日：2024-08-08

申请号：US18562387

申请日：2022-05-23

Applicant: Pfizer Inc.

Inventor： Robert George Konrad Donald ,  Aniruddha Sasmal

IPC: C12N1/20 ,  C07K14/26 ,  C12N9/10 ,  C12N9/90 ,  C12N15/52 ,  C12N15/70 ,  C12R1/19

CPC classification number: C12N1/205 ,  C07K14/26 ,  C12N9/1051 ,  C12N9/90 ,  C12N15/52 ,  C12N15/70 ,  C12R2001/19 ,  C12Y504/99009

Abstract: This invention provides a recombinant Escherichia coli (E. coli) host cell for producing a Klebsiella pneumoniae (K. pneumoniae) O-antigen, wherein the E. coli host cell comprises a polynucleotide encoding the K. pneumoniae O-antigen, including methods of producing and purifying the K. pneumoniae O-antigen.

公开(公告)号：US20220152181A1

公开(公告)日：2022-05-19

申请号：US17509110

申请日：2021-10-25

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Robert George Konrad Donald ,  Jacqueline Marie Lypowy ,  Rosalind Pan

IPC: A61K39/108 ,  A61P31/04 ,  A61P37/04

Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.